WET MACULAR DEGENERATION
Clinical trials for WET MACULAR DEGENERATION explained in plain language.
Never miss a new study
Get alerted when new WET MACULAR DEGENERATION trials appear
Sign up with your email to follow new studies for WET MACULAR DEGENERATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a new eye injection save vision in wet AMD?
Disease control CompletedThis clinical trial is testing whether an experimental eye injection called ONS-5010 (bevacizumab) can help preserve vision in people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The study will compare ONS-5010 to an existing treatment, ranibiz…
Matched conditions: WET MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: Outlook Therapeutics, Inc. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New eye drug aims to save sight in wet AMD
Disease control CompletedThis trial tests whether an experimental drug called ONS-5010 (a form of bevacizumab) works as well as an approved drug, Lucentis, for treating wet age-related macular degeneration (AMD). Wet AMD causes rapid vision loss due to abnormal blood vessels leaking fluid in the eye. Abo…
Matched conditions: WET MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: Outlook Therapeutics, Inc. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Eye injection aims to tame leading causes of blindness
Disease control CompletedThis study tests the safety of an experimental eye injection called ONS-5010 (bevacizumab) in people with vision loss from wet age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion. Participants receive the injection and are monitored for side…
Matched conditions: WET MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: Outlook Therapeutics, Inc. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Eye drops could replace needles for wet AMD?
Disease control CompletedThis study tested three different doses of SYL1801 eye drops in 99 people with wet age-related macular degeneration (AMD). The goal was to see if the drops are safe and can improve or maintain vision. Participants used the drops for a set period, and their vision was measured aft…
Matched conditions: WET MACULAR DEGENERATION
Phase: PHASE2 • Sponsor: Sylentis, S.A. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC